ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 224 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $389,708 | -90.5% | 18,700 | -89.0% | 0.00% | -90.0% |
Q2 2023 | $4,081,080 | +1663.0% | 170,400 | +1285.4% | 0.01% | +900.0% |
Q1 2023 | $231,486 | -1.1% | 12,300 | -25.9% | 0.00% | 0.0% |
Q2 2022 | $234,000 | -83.0% | 16,600 | -70.8% | 0.00% | -75.0% |
Q1 2022 | $1,378,000 | -71.8% | 56,900 | -70.0% | 0.00% | -69.2% |
Q1 2021 | $4,889,000 | -78.4% | 189,500 | -55.2% | 0.01% | -78.3% |
Q4 2020 | $22,592,000 | -14.2% | 422,600 | -33.8% | 0.06% | -20.0% |
Q3 2020 | $26,326,000 | +35.8% | 638,200 | +59.5% | 0.08% | +31.6% |
Q2 2020 | $19,393,000 | +643.9% | 400,100 | +548.5% | 0.06% | +470.0% |
Q1 2020 | $2,607,000 | -41.8% | 61,700 | -41.1% | 0.01% | 0.0% |
Q4 2019 | $4,483,000 | +16.1% | 104,800 | -2.3% | 0.01% | +11.1% |
Q3 2019 | $3,862,000 | +102.6% | 107,300 | +50.5% | 0.01% | +80.0% |
Q2 2019 | $1,906,000 | -2.9% | 71,300 | -2.5% | 0.01% | 0.0% |
Q1 2019 | $1,963,000 | +122.8% | 73,100 | +34.1% | 0.01% | +150.0% |
Q4 2018 | $881,000 | – | 54,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |